Drug Profile
LT 1951
Alternative Names: Nona-L-arginine - Lumen; oligo-L-arginineLatest Information Update: 27 Sep 2016
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Lumen Therapeutics; Toronto General Hospital
- Class Amino acids
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 15 Sep 2015 No recent reports on development identified - Phase-I/II for Coronary artery restenosis in Canada (Extracorporeal)
- 23 Mar 2005 Phase-I/II clinical trials in Coronary artery restenosis in Canada (Extracorporeal)